Haolin Xu

Haolin Xu

Auto-generated profile, based on publicly available information

Haolin Xu

Duke Clinical Research Institute, Durham, NC

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in JACC
Verified
Journal Article
Closed access
KSKevin S. Shah
Kevin S. Shah
HXHaolin Xu
Haolin Xu
RMRoland A. Matsouaka
Roland A. Matsouaka
DBDeepak L. Bhatt
Deepak L. Bhatt
PHPaul A. Heidenreich
Paul A. Heidenreich
GFGregg C. Fonarow
Gregg C. Fonarow

14 March 2017 in JAMA
Verified
Journal Article
Open access
PDF file
YXYing Xian
Ying Xian
EOEmily C. O’bRien
Emily C. O’bRien
LLLi Liang
Li Liang
HXHaolin Xu
Haolin Xu
LSLee H. Schwamm
Lee H. Schwamm
EPEric D. Peterson
Eric D. Peterson
Quiz Ref ID Atrial fibrillation (AF) is an independent risk factor for stroke, increases stroke risk by a factor of 4 to 5, and accounts for 10% to 15% of all ischemic strokes.1,2 While the burden of AF-related stroke is high, AF is a potentially treatable risk factor. Numerous studies have demonstrated that vitamin K antagonists, such as warfarin, or non–vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, reduce the risk of ischemic stroke.3-8 Based on these data, current guidelines recommend adjusted-dose warfarin or NOACs over aspirin for stroke prevention in high-risk patients with AF.1,9

1 December 2016 in American Heart Journal
Verified
Journal Article
Closed access
JEJustin B. Echouffo-Tcheugui
Justin B. Echouffo-Tcheugui
HXHaolin Xu
Haolin Xu
ADAdam D. DeVore
Adam D. DeVore
PSPhillip J. Schulte
Phillip J. Schulte
JBJaved Butler
Javed Butler
GFGregg C. Fonarow
Gregg C. Fonarow

17 April 2018 in Journal of the American Heart Association
Verified
Journal Article
Open access
SLShanshan Li
Shanshan Li
GFGregg C. Fonarow
Gregg C. Fonarow
KMKenneth Mukamal
Kenneth Mukamal
HXHaolin Xu
Haolin Xu
RMRoland A. Matsouaka
Roland A. Matsouaka
DBDeepak L. Bhatt
Deepak L. Bhatt
Background: Cardiac rehabilitation ( CR ) referral is recommended for eligible patients, regardless of sex or race. It is unclear whether inequality in CR referral practices was associated with patients’ long‐term survival. Methods and Results: We linked the American Heart Association Get With The Guidelines Coronary Artery Disease registry with Medicare claims data for 48 993 coronary artery disease patients from 365 hospitals across the United States between 2003 and 2009. We used generalized estimation equations to estimate the association between CR referral and mortality accounting for clustering within hospitals. Between 2003 and 2009, only 40% of eligible patients received CR referrals. Females were 12% less likely to receive CR referral compared with males. Black, Hispanic, and Asian patients were 20%, 36%, and 50% less likely, respectively, to receive CR referral than white patients. CR referral was associated with 40% lower 3‐year all‐cause mortality. Women and minorities who received CR referral at hospital discharge had significantly lower mortality compared with those who did not (odds ratios=0.61 [95% confidence interval, 0.56–0.66] for women, 0.75 [95% confidence interval, 0.63–0.88] for black, 0.62 [95% confidence interval, 0.50–0.79] for Hispanic, and 0.63 [95% confidence interval, 0.46–0.85] for Asian patients). Seven percent of the black versus white mortality gap could potentially be reduced by equitable CR referral. Conclusions: CR referral rates at hospital discharge remained low. Gaps in receiving CR referral at hospital discharge were large for women and minorities, and the mortality gap could potentially be reduced through elimination of inequality in CR referral.

1 January 2017 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
YXYing Xian
Ying Xian
HXHaolin Xu
Haolin Xu
BLBarbara Lytle
Barbara Lytle
JBJason Blevins
Jason Blevins
EPEric D. Peterson
Eric D. Peterson
GFGregg C. Fonarow
Gregg C. Fonarow
Background—: The implementation of Target: Stroke Phase I, the first stage of the American Heart Association’s national quality improvement initiative to accelerate door-to-needle (DTN) times, was associated with an average 15-minute reduction in DTN times. Target: Stroke phase II was launched in April 2014 with a goal of promoting further reduction in treatment times for tissue-type plasminogen activator (tPA) administration. Methods and Results—: We conducted a second survey of Get With The Guidelines-Stroke hospitals regarding strategies used to reduce delays after Target: Stroke and quantify their association with DTN times. A total of 16 901 ischemic stroke patients were treated with intravenous tPA within 4.5 hours of symptom onset from 888 surveyed hospitals between June 2014 and April 2015. The patient-level median DTN time was 56 minutes (interquartile range, 42–75), with 59.3% of patients receiving intravenous tPA within 60 minutes and 30.4% within 45 minutes after hospital arrival. Most hospitals reported routinely using a majority of Target: Stroke key practice strategies, although direct transport of patients to computed tomographic/magenetic resonance imaging scanner, premix of tPA ahead of time, initiation of tPA in brain imaging suite, and prompt data feedback to emergency medical services providers were used less frequently. Overall, we identified 16 strategies associated with significant reductions in DTN times. Combined, a total of 20 minutes (95% confidence intervals 15–25 minutes) could be saved if all strategies were implemented. Conclusions—: Get With The Guidelines-Stroke hospitals have initiated a majority of Target: Stroke–recommended strategies to reduce DTN times in acute ischemic stroke. Nevertheless, certain strategies were infrequently practiced and represent a potential immediate target for further improvements.

9 February 2018 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JEJustin B Echouffo-Tcheugui
Justin B Echouffo-Tcheugui
HXHaolin Xu
Haolin Xu
RMRoland A Matsouaka
Roland A Matsouaka
YXYing Xian
Ying Xian
LSLee H Schwamm
Lee H Schwamm
GFGregg C. Fonarow
Gregg C. Fonarow
There is a paucity of data on the influence of diabetes on long-term outcomes after ischaemic stroke (IS). We assessed whether outcomes after IS differ between patients with and without diabetes. Patients aged ≥65 years (n = 409 060) in Get With The Guidelines-Stroke (nationwide registry of stroke patients from 1690 sites in the USA) were followed for 3 years post-discharge. The outcomes of interest were mortality, cardiovascular and non-cardiovascular hospitalizations, heart failure (HF), and recurrence of IS/transient ischaemic attack (TIA). Patients with diabetes (29.6%) were younger and had more comorbidities. At 3 years post-discharge after IS, diabetes was associated with higher risks of adverse outcomes: all-cause mortality [cumulative incidence 46.0% vs. 44.2%, absolute difference (AD) 1.8%; adjusted hazard ratio (aHR) 1.24, 95% confidence interval 1.23–1.25], all-cause readmission (71.3% vs. 63.7%, AD 7.6%; aHR 1.22, 1.21–1.23), composite of mortality and all-cause readmission (84.1% vs. 79.3%, AD 4.8%; aHR 1.21, 1.20–1.22), composite of mortality and cardiovascular readmission (69.5% vs. 64.3%, AD 5.2%; aHR 1.19, 1.18–1.20), IS/TIA readmission (15.9% vs. 13.3%, AD 2.6%; aHR 1.18, 1.16–1.20), HF readmission (10.3% vs. 6.4%, AD 3.9%; aHR 1.60, 1.56–1.64), non-cardiovascular readmission (58.3% vs. 50.3%, AD 8.0%; aHR 1.28, 1.26–1.29), and non-IS/TIA readmission (67.6% vs. 59.7%, AD 7.9%; aHR 1.23, 1.22–1.25). Accounting for the initial severity of stroke using the National Institute of Health Stroke Scale as well as using propensity score matching method as a sensitivity analysis, did not modify the results. Among older IS patients diabetes was associated with increased risks of death, cardiovascular and non-cardiovascular hospitalizations, HF, and IS/TIA recurrence.